ATRIPLA (Efavirenz/Emtricitabine/ Tenofovir)
ATRIPLA (Efavirenz/Emtricitabine/ Tenofovir)
  • Load image into Gallery viewer, ATRIPLA (Efavirenz/Emtricitabine/ Tenofovir)
  • Load image into Gallery viewer, ATRIPLA (Efavirenz/Emtricitabine/ Tenofovir)

ATRIPLA (Efavirenz/Emtricitabine/ Tenofovir)

Regular price
$1,759.99 USD
Sale price
$1,759.99 USD
Regular price
Sold out
Unit price
Shipping calculated at checkout.


What is this medication?

ATRIPLA (Efavirenz/Emtricitabine/Tenofovir)
Antiretroviral, Reverse Transcriptase Inhibitor

ATRIPLA (Efavirenz/Emtricitabine/Tenofovir) is a combination drug consisting of two nucleoside analog HIV-1 reverse transcriptase inhibitors and 1 non-nucleoside HIV-1 reverse transcriptase inhibitor that is used alone or in combination with other antiretroviral agents for the treatment of HIV-1 infection.

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including tenofovir disoproxil fumarate, a component of ATRIPLA.

ATRIPLA is not approved for the treatment of chronic hepatitis B virus (HBV) infection.  Severe acute exacerbations of hepatitis B have been reported in patients coinfected with HBV and HIV-1 who have discontinued EMTRIVA or VIREAD, two of the components of ATRIPLA. 
Hepatic function should be monitored closely in these patients. If appropriate, initiation of anti-hepatitis B therapy may be warranted.

How does this medication work? 

Efavirenz is a non-nucleoside reverse transcriptase inhibitor of HIV-1. It consequently blocks the RNA-dependent and DNA-dependent DNA polymerase activities including HIV-1 replication. 

Emtricitabine is a nucleoside reverse transcriptase inhibitor; cytosine analogue that is phosphorylated intracellularly to emtricitabine 5′-triphosphate which interferes with HIV viral RNA dependent DNA polymerase resulting in inhibition of viral replication.

Tenofovir disoproxil fumarate is a nucleotide reverse transcriptase inhibitor; analog of adenosine 5′-monophosphate that interferes with the HIV viral RNA dependent DNA polymerase resulting in inhibition of viral replication. TDF is first converted intracellularly by hydrolysis to tenofovir and subsequently phosphorylated to the active tenofovir diphosphate. Tenofovir inhibits replication of HBV by inhibiting HBV polymerase.

How should I take this medication? 

Oral: Take 1 tablets once daily.

How to Take: Take on an empty stomach at bedtime to reduce the impact of CNS symptoms.

What should I watch for while using this medication? 

Before starting ATRIPLA (Efavirenz/Emtricitabine/Tenofovir), make sure your physician is aware of any allergies or medications you currently take. The combination of Efavirenz/Emtricitabine/Tenofovir can cause central nervous system symptoms such as insomnia, abnormal dreams and hallucinations along with impaired concentration, dizziness and drowsiness. Efavirenz/Emtricitabine/Tenofovir has been associated with a decrease in bone mineral density, fat redistribution, hepatotoxicity, osteomalacia with renal dysfunction, psychiatric effects, QT prolongation, hepatic and/or renal toxicity and seizures.

What if I miss a dose?

If you miss a dose of medication, try to take it as soon as possible. However, if it is almost time for your next dose, take only that scheduled dose. Do not take double or extra doses.

How should I store this medication?

Keep out of the reach of children at all times. Store at room temperature, 59 to 86° F (15 to 30° C). Protect from light. Keep the container tightly closed. Properly dispose of any unused medication after the expiration date.

What are the possible side effects of using this medication?

Abnormal dreams, hypercholesterolemia, depression, fatigue, dizziness, headache, anxiety, insomnia, skin rash, diarrhea, nausea, vomiting, hematuria, elevated liver enzymes, sinusitis, upper respiratory tract infection, nasopharyngitis.

Note this is not a complete list of side effects for ATRIPLA (Efavirenz/Emtricitabine/Tenofovir), only common ones.